<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288481</url>
  </required_header>
  <id_info>
    <org_study_id>TBA-354-CL-001</org_study_id>
    <nct_id>NCT02288481</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study With a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alliance for TB Drug Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and tolerability of single oral doses&#xD;
      of TBA-354 when administered to healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single ascending dose study conducted&#xD;
      at one study center in the United States. Six (6) cohorts of 8 subjects each (6 active and 2&#xD;
      placebo), with one cohort crossing over to assess food effect, are planned for evaluation.&#xD;
      Subjects will participate in only one cohort.&#xD;
&#xD;
      Safety will be assessed throughout the study; serial ECGs and serial blood samples will be&#xD;
      collected for the safety and PK assessment of TBA-354.&#xD;
&#xD;
      Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor,&#xD;
      in conjunction with the Principal Investigator, has determined that adequate safety,&#xD;
      tolerability and PK from the previous cohort has been demonstrated to permit proceeding to&#xD;
      the next cohort. Upon review of cohort data, the Sponsor, in conjunction with the Principal&#xD;
      Investigator, may decide to:&#xD;
&#xD;
        1. Escalate dose as planned.&#xD;
&#xD;
        2. Evaluate an intermediate dose level prior to proceeding to the next planned dose level&#xD;
           if concerns arise from signs and symptoms that do not warrant ceasing escalation as&#xD;
           described above.&#xD;
&#xD;
        3. Repeat a given dose level in a new cohort of subjects.&#xD;
&#xD;
        4. Halt the study.&#xD;
&#xD;
      Blinded interim PK analyses will be performed for the dose escalation decisions, to select&#xD;
      the intermediate dose for the food effect cohort, and to reconsider the sampling time points&#xD;
      as the study progresses.&#xD;
&#xD;
      Subjects will be housed in the Celerion clinic from at least 24 hours prior (from Day -2),&#xD;
      until 48 hours after dosing. Subjects will return for subsequent follow up safety and PK&#xD;
      assessments on Days 4 to 7 and will be contacted via a phone call for follow-up questioning&#xD;
      about adverse events 7 days later (Study Day 14). One cohort will return after a washout of&#xD;
      at least 14 days or five half-lives (whichever is longer) of their fasting dose to receive&#xD;
      the same intermediate dose (TBD mg) under fed conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study will be the number and severity of treatment emergent adverse events (TEAEs) following single doses of TBA-354 and placebo.</measure>
    <time_frame>Day 1, 2, 4, 5, 6, 7, 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of TBA-354 in plasma following single oral doses. Cmax, AUC0-24</measure>
    <time_frame>Day 1 (Hour 0, 1, 2, 4, 6, 7, 8, 12, 16), Day 2 (Hour 20, 24, 30, 36, 42), Follow up (Hour 72, 96, 120, 144)</time_frame>
    <description>Tmax: Time of the maximum drug concentration (obtained without interpolation). Cmax: Maximum observed drug concentration. AUC0-24: Area under concentration time curve 0 to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the Pharmacokinetics parameters of TBA-354 in plasma following an intermediate single oral dose. Cmax, AUC0-24</measure>
    <time_frame>Day 1 (Hour 0, 1, 2, 4, 6, 7, 8, 12, 16), Day 2 (Hour 20, 24, 30, 36, 42), Follow up (Hour 72, 96, 120, 144)</time_frame>
    <description>Tmax: Time of the maximum drug concentration (obtained without interpolation). Cmax: Maximum observed drug concentration. AUC0-24: Area under concentration time curve 0 to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects/time points with abnormal findings in safety electrocardiogram</measure>
    <time_frame>Screening; Day 1 (Hour 0, 1, 2, 4, 6, 8, 12, 16); Day 2 Hour 20, 24, 30, 36 and 48; Follow up Hour 144</time_frame>
    <description>Calculated in terms of QT corrected for heart rate according to Fridericia's corrected formula (QTcF) outliers (QTcF &gt; 450, &gt; 480, and &gt; 500 msec; and change-from-baseline QTcF &gt; 30 and &gt; 60 msec).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected safety electrocardiogram Change-from-baseline heart rate</measure>
    <time_frame>Screening; Day 1 (Hour 0, 1, 2, 4, 6, 8, 12, 16); Day 2 Hour 20, 24, 30, 36 and 48; Follow up Hour 144</time_frame>
    <description>Change-from-baseline heart rate, QT corrected for heart rate according to Fridericia's corrected formula (QTcF), PR, QRS, QT, and incidence of abnormal T-wave morphology from cardiodynamic electrocardiograms extracted from the pre-specified time points.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 10 mg TBA-354</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 25 mg TBA-354</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 60 mg TBA-354</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 150 mg TBA-354</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 400 mg TBA-354</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 1000 mg TBA-354</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBA-354</intervention_name>
    <description>TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.</description>
    <arm_group_label>Cohort 1 10 mg TBA-354</arm_group_label>
    <arm_group_label>Cohort 2 25 mg TBA-354</arm_group_label>
    <arm_group_label>Cohort 3 60 mg TBA-354</arm_group_label>
    <arm_group_label>Cohort 4 150 mg TBA-354</arm_group_label>
    <arm_group_label>Cohort 5 400 mg TBA-354</arm_group_label>
    <arm_group_label>Cohort 6 1000 mg TBA-354</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Suspension</description>
    <arm_group_label>Cohort 1 placebo</arm_group_label>
    <arm_group_label>Cohort 2 placebo</arm_group_label>
    <arm_group_label>Cohort 3 placebo</arm_group_label>
    <arm_group_label>Cohort 4 placebo</arm_group_label>
    <arm_group_label>Cohort 5 placebo</arm_group_label>
    <arm_group_label>Cohort 6 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must fulfill all of the following inclusion criteria and none of the exclusion&#xD;
        criteria to be eligible for participation in the study, unless otherwise specified.&#xD;
        Subjects must continue to meet all inclusion criteria to be able to participate in the Food&#xD;
        Effect study.&#xD;
&#xD;
          1. Healthy adult male and females of non-childbearing potential, 19 to 50 years of age&#xD;
             (inclusive) at the time of screening.&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) and a body weight of no less than 50&#xD;
             kg.&#xD;
&#xD;
          3. Medically healthy with no clinically significant screening results (e.g., laboratory&#xD;
             profiles, medical histories, vital signs, electrocardiograms (ECGs), physical&#xD;
             examination) as deemed by the Principal Investigator.&#xD;
&#xD;
          4. No use of tobacco or nicotine containing products (including smoking cessation&#xD;
             products), for a minimum of 6 months prior to dosing.&#xD;
&#xD;
          5. Females of non-childbearing potential have undergone one of the following&#xD;
             sterilization procedures at least 6 months prior to dosing:&#xD;
&#xD;
             i. Hysteroscopic sterilization&#xD;
&#xD;
             ii. Bilateral tubal ligation or bilateral salpingectomy&#xD;
&#xD;
             iii. Hysterectomy&#xD;
&#xD;
             iv. Bilateral oophorectomy&#xD;
&#xD;
             v. or be postmenopausal with amenorrhea for at least 1 year prior to the first dose&#xD;
             with serumfollicle-stimulating hormone (FSH) levels consistent with postmenopausal&#xD;
             status at screening.&#xD;
&#xD;
          6. Non-vasectomized males (or males vasectomized less than 120 days prior to study&#xD;
             start), must agree to the following during study participation and for 90 days&#xD;
             following the last administration of study drug:&#xD;
&#xD;
               1. use a condom with spermicide while engaging in sexual activity or be sexually&#xD;
                  abstinent&#xD;
&#xD;
               2. not donate sperm during this time.&#xD;
&#xD;
             In the event the sexual partner is surgically sterile, use of a condom with spermicide&#xD;
             is not necessary. None of the restrictions listed above are required for vasectomized&#xD;
             males whose procedure was performed more than 120 days prior to study start.&#xD;
&#xD;
          7. Willing to answer inclusion and exclusion criteria questionnaire at check-in.&#xD;
&#xD;
          8. Subject understands study procedures and provides written informed consent for the&#xD;
             trial.&#xD;
&#xD;
          9. Be able to comply with the protocol and the assessments therein.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the study if there is evidence of any of the following&#xD;
        criteria at screening or check-in, as appropriate. Subjects must continue to meet none of&#xD;
        the Exclusion Criteria in order to participate in the Food Effect study.&#xD;
&#xD;
          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,&#xD;
             or psychiatric disease.&#xD;
&#xD;
          2. History of any illness that, in the opinion of the Principal Investigator, might&#xD;
             confound the results of the study or poses an additional risk to the subject by their&#xD;
             participation in the study.&#xD;
&#xD;
          3. Surgery within the past 90 days prior to dosing as determined by the Principal&#xD;
             Investigator to be clinically relevant.&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the past 2 years.&#xD;
&#xD;
          5. Hypersensitive or idiosyncratic reactions to compounds related to TBA-354 (e.g.,&#xD;
             nitroimidazoles such as metronidazole, etc.).&#xD;
&#xD;
          6. Female subjects who are pregnant or lactating.&#xD;
&#xD;
          7. Positive results for the urine drug/alcohol screen at screening or check-in.&#xD;
&#xD;
          8. Positive urine cotinine at screening.&#xD;
&#xD;
          9. Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B&#xD;
             Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV).&#xD;
&#xD;
         10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
             screening.&#xD;
&#xD;
         11. Heart rate is lower than 40 bpm or higher than 99 bpm at screening.&#xD;
&#xD;
         12. Any clinically significant ECG abnormality at Screening (as deemed by the Principal&#xD;
             Investigator and the Sponsor's Medical Monitor).&#xD;
&#xD;
             NOTE: The following can be considered not clinically significant without consulting&#xD;
             Sponsor's Medical Monitor:&#xD;
&#xD;
             i. Mild first degree A-V block (P-R interval &lt;0.23 sec)&#xD;
&#xD;
             ii. Right or left axis deviation&#xD;
&#xD;
             iii. Incomplete right bundle branch block&#xD;
&#xD;
             iv. Isolated left anterior fascicular block (left anterior hemiblock) in younger&#xD;
             athletic subjects&#xD;
&#xD;
         13. QTcF interval &gt;450 msec for males or &gt;470 msec for females (the average value for the&#xD;
             replicate ECG at screening and Check-In), or history of prolonged QT syndrome.&#xD;
&#xD;
         14. Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a&#xD;
             condition that could be causative of sudden death (such as known coronary artery&#xD;
             disease, congestive heart failure or terminal cancer).&#xD;
&#xD;
         15. History of one or any combination of, the following:&#xD;
&#xD;
               1. Seizures or seizure disorders, (excluding febrile seizures of childhood).&#xD;
&#xD;
               2. Brain trauma or brain surgery.&#xD;
&#xD;
               3. Any serious disorder of the CNS or related neurological system, particularly one&#xD;
                  that may lower the seizure threshold.&#xD;
&#xD;
         16. Use of any prescription medication within 14 days prior to dosing.&#xD;
&#xD;
         17. Use of any over-the-counter (OTC) medication, including herbal products and vitamins,&#xD;
             within the 7 days prior to dosing. Up to 2 grams per day of acetaminophen is allowed&#xD;
             at the discretion of the Principal Investigator.&#xD;
&#xD;
         18. Use of any drugs or substances known to be significant inhibitors of CYP enzymes&#xD;
             and/or significant inhibitors or substrates of P-gp and/or OATP within 14 days prior&#xD;
             to the first dose of study drug.&#xD;
&#xD;
         19. Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp,&#xD;
             including St. John's Wort, within 28 days prior to the first dose of study drug.&#xD;
&#xD;
         20. Use of any drugs or substance known to lower the seizure threshold.&#xD;
&#xD;
         21. Blood donation or significant blood loss within 56 days prior to dosing.&#xD;
&#xD;
         22. Plasma donation within 7 days prior to dosing.&#xD;
&#xD;
         23. Participation in another clinical trial within 28 days prior to dosing.&#xD;
&#xD;
         24. Prior treatment with investigational products PA-824 or OPC-67683.&#xD;
&#xD;
         25. Consumption of the following prior to dosing period:&#xD;
&#xD;
               1. Alcohol 48 hours prior to dosing&#xD;
&#xD;
               2. Grapefruit/Mandarin Oranges 10 days prior to dosing&#xD;
&#xD;
               3. Caffeine/Xanthine 24 hours prior to dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gartner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>TBA-354</keyword>
  <keyword>Pulmonary Tuberculosis</keyword>
  <keyword>TB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

